IL10 and glioma: Intrinsic tumor resistance, such as the WNT-β-catenin signaling pathway, prevents antitumor immune responses by promoting the release of the immunosuppressive cytokine IL-10 and is a major challenge in ICI therapy for glioma [27,28].